Progress of research on the roles of extracellular chaperones in the pathogenesis of amyloidosis

doi:10.3877/cma.j.issn.2095-3216.2021.05.008

Abstract

Abstract:

Amyloidosis belongs to the protein conformational diseases, the main pathogenesis of which includes the imbalance of proteostasis and the misfolding of precursor proteins. Similar to the role of intracellular chaperones, extracelluar chaperones can facilitate the correct folding of proteins and clean the misfolded or aggregated proteins. It is noted that amyloidosis is accompanied by the deposition of extracelluar chaperones, but their roles in the occurrence and development of amyloidosis are still unclear. This article listed several common chaperones and reviewed their structure, function, and roles in the pathogenesis of amyloidosis.

Key words: Amyloidosis, Extracelluar chaperones, Proteostasis, Amyloid fibril, Precursor protein

Shuang Wang, Suxia Wang. Progress of research on the roles of extracellular chaperones in the pathogenesis of amyloidosis[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2021, 10(05): 278-283.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2021.05.008

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2021/V10/I05/278

Figures/Tables 2

References 43

[1]	Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis [J]. Nature, 2011, 475(7356): 324-332.
[2]	Wyatt AR, Yerbury JJ, Ecroyd H, et al. Extracellular chaperones and proteostasis [J]. Annu Rev Biochem, 2013, 82: 295-322.
[3]	Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis [J]. Lancet, 2016, 387(10038): 2641-2654.
[4]	Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee [J]. Amyloid, 2018, 25(4): 215-219.
[5]	Iadanza MG, Jackson MP, Hewitt EW, et al. A new era for understanding amyloid structures and disease [J]. Nat Rev Mol Cell Biol, 2018, 19(12): 755-773.
[6]	Cathcart ES, Shirahama T, Cohen AS. Isolation and identification of a plasma component of amyloid [J]. Biochim Biophys Acta, 1967, 147(2): 392-393.
[7]	Hind CRK, Collins PM, Caspi D, et al. Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits [J]. Lancet, 1984, 2(8399): 376-378.
[8]	Coker AR, Purvis A, Baker D, et al. Molecular chaperone properties of serum amyloid P component [J]. FEBS Lett, 2000, 473(2): 199-202.
[9]	Nelson SR, Tennent GA, Sethi D, et al. Serum amyloid P component in chronic renal failure and dialysis [J]. Clin Chim Acfa, 1991, 200(2-3): 191-199.
[10]	Pepys MB, Dash AC, Markham RE, et al. Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum [J]. Clin Exp Immunol, 1978, 32(1): 119-124.
[11]	Levo Y, Shalit M, Tur-Kaspa R. Serum amyloid P component as a marker of liver disease [J]. Am J Gastroenterol, 1982, 77(6): 427-430.
[12]	Cox N, Pilling D, Gomer RH. Serum amyloid P: a systemic regulator of the innate immune response [J]. J Leukoc Biol, 2014, 96(5): 739-743.
[13]	Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis [J]. Proc Natl Acad Sci USA, 1995, 92(10): 4299-4303.
[14]	Mold M, Shrive AK, Exley C. Serum amyloid P component accelerates the formation and enhances the stability of amyloid fibrils in a physiologically significant under-saturated solution of amyloid-β42 [J]. J Alzheimers Dis, 2012, 29(4): 875-881.
[15]	Botto M, Hawkins PN, Bickerstaff MC, et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene [J]. Nat Med, 1997, 3(8): 855-859.
[16]	Ozawa D, Nomura R, Mangione, PP, et al. Multifaceted anti-amyloidogenic and pro-amyloidogenic effects of C-reactive protein and serum amyloid P component in vitro [J]. Sci Rep, 2016, 6: 29077.
[17]	Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits [J]. Nature, 2010, 468(7320): 93-97.
[18]	Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component [J]. N Engl J Med, 2015, 373(12): 1106-1114.
[19]	Richards DB, Cookson LM, Barton SV, et al. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis [J]. Sci Transl Med, 2018, 10(422): eaan3128.
[20]	Fritz IB, Burdzy K, Sétchell B, et al. Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interactions in vitro [J]. Biol Reprod, 1983, 28(5): 1173-1188.
[21]	Jenne DE, Tschopp J. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid [J]. Proc Natl Acad Sci USA, 1989, 86(18): 7123-7127.
[22]	de Silva HV, Harmony JA, Stuart WD, et al. Apolipoprotein J: structure and tissue distribution [J]. Biochemistry, 1990, 29(22): 5380-5389.
[23]	Poon S, Rybchyn MS, Easterbrook-Smith SB, et al. Clusterin is an ATP-independent chaperone with a very broad substrate specificity that stabilizes stressed proteins in a folding-competent state [J]. Biochemistry, 2000, 39(51): 15953-15960.
[24]	Poon S, Rybchyn MS, Easterbrook-Smith SB, et al. Mildly acidic pH activates the extracellular molecular chaperone clusterin [J]. J Biol Chem, 2002, 277(42): 39532-39540.
[25]	Franco DA, Truran S, Camelia B, et al. Protective role of clusterin in preserving endothelial function in AL amyloidosis [J]. Atherosclerosis, 2012, 225(1): 220-223.
[26]	Yerbury JJ, Poon S, Meehan S, et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures [J]. FASEB J, 2007, 21(10): 2312-2322.
[27]	Lee KW, Lee DH, Son H, et al. Clusterin regulates transthyretin amyloidosis [J]. Biochem Biophys Res Commun, 2009, 388(2): 256-260.
[28]	DeMattos RB, O′dell MA, Parsadanian M, et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer′s disease [J]. Proc Natl Acad Sci USA, 2002, 99(16): 10843-10848.
[29]	DeMattos RB, Cirrito JR, Parsadanian M, et al. ApoE and clusterin cooperatively suppress Aβ levels and deposition: evidence that ApoE regulates extracellular Aβ metabolism in vivo [J]. Neuron, 2004, 41(2): 193-202.
[30]	Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer′s disease [J]. Nat Genet, 2009, 41(10): 1088-1093.
[31]	Weisgraber KH, Rall SC Jr, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms [J]. J Biol Chem, 1981, 256(17): 9077-9083.
[32]	Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty’ allele? [J]. Ann Hum Genet, 1999, 63(Pt4): 301-310.
[33]	Chen J, Li Q, Wang J. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions [J]. Proc Natl Acad Sci USA, 2011, 108(36): 14813-14818.
[34]	Baumann MH, Kallijärvi J, Lankinen H, et al. Apolipoprotein E includes a binding site which is recognized by several amyloidogenic polypeptides [J]. Biochem J, 2000, 349(Pt 1): 77-84.
[35]	Huang Y, Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases [J]. Neurobiol Dis, 2014, 72(Pt A): 3-12.
[36]	Soto C, Castano EM, Prelli F, et al. Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer’s, gelsolin and AA amyloids [J]. FEBS Lett, 1995, 371(2): 110-114.
[37]	Naiki H, Gejyo F, Nakakuk K. Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer′s β-amyloid fibril formation in vitro [J]. Biochemistry, 1997, 36(20): 6243-6250.
[38]	Liu CC, Zhao N, Fu Y, et al. ApoE4 accelerates early seeding of amyloid pathology [J]. Neuron, 2017, 96(5): 1024-1032.
[39]	Huynh TPV, Liao F, Francis CM, et al. Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of β-amyloidosis [J]. Neuron, 2017, 96(5): 1013-1023.
[40]	Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology [J]. Neurobiol Aging, 2004, 25(5): 641-650.
[41]	Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer′s disease: advances in genetics，pathophysiology, and therapeutic approaches [J]. Lancet Neurol, 2021, 20(1): 68-80.
[42]	Cummings JL, Zhong K, Kinney JW, et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer′s disease [J]. Alzheimers Res Ther, 2016, 8: 4.
[43]	Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis [J]. Nature, 2002, 417(16): 254-259.

疾病	前体蛋白	伴侣蛋白
疾病	前体蛋白	血清淀粉样P物质	载脂蛋白E	凝聚素	α2微球蛋白	触珠蛋白
轻链型淀粉样变	免疫球蛋白轻链	√	√	√
血清淀粉样蛋白A型淀粉样变	血清淀粉样蛋白A	√	√	√
甲状腺素运载蛋白型淀粉样变	甲状腺素运载蛋白	√	√	√
白细胞趋化因子2型淀粉样变	白细胞趋化因子2	√	√	√
阿尔兹海默症	淀粉样β蛋白	√	√	√	√	√
透析相关淀粉样变	β2微球蛋白				√	√

疾病	前体蛋白	伴侣蛋白
疾病	前体蛋白	血清淀粉样P物质	载脂蛋白E	凝聚素	α2微球蛋白	触珠蛋白
轻链型淀粉样变	免疫球蛋白轻链	√	√	√
血清淀粉样蛋白A型淀粉样变	血清淀粉样蛋白A	√	√	√
甲状腺素运载蛋白型淀粉样变	甲状腺素运载蛋白	√	√	√
白细胞趋化因子2型淀粉样变	白细胞趋化因子2	√	√	√
阿尔兹海默症	淀粉样β蛋白	√	√	√	√	√
透析相关淀粉样变	β2微球蛋白				√	√

Please choose a citation manager

Content to export